FCP

Notable Labs is a clinical-stage precision oncology company focused on developing a platform to predict patient responses to cancer therapies. The company's proprietary Predictive Precision Medicine Platform (PPMP) uses high-throughput flow cytometry and automated analysis to test a patient's own cancer cells against various drug candidates ex vivo. By identifying which patients are most likely to respond to a specific treatment, Notable aims to accelerate drug development and improve clinical outcomes. Their lead program, volasertib, is being developed for patients with relapsed/refractory acute myeloid leukemia (AML) who are predicted to be responders by the PPMP.